FDA Clearance Tracker · P030017-S381
WaveWriter Alpha SCS System, WaveWriter Alpha Prime SCS System
Last checked: Nov 20, 2026Latest source record: Mar 17, 2025 (this decision)Source: openFDAMethods & limitations
Decided
Mar 17, 2025
Approved
Time to decision
87 days
Received Dec 20, 2024. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA supplement
Normal 180 Day Track
Device class
Class III
The decision
- FDA number
- P030017-S381
- Device name
- WaveWriter Alpha SCS System, WaveWriter Alpha Prime SCS System
- Applicant
- Boston Scientific Corp
- Applicant location
- Valencia, CA
- Received
- Dec 20, 2024
- Decided
- Mar 17, 2025
- Decision
- Approved
- Supplement type
- Normal 180 Day Track
- Reason for supplement
- Labeling Change - Indications/instructions/shelf life/tradename
- Original approval
- P030017
Device type
- Device class
- Class III
FDA's approval statement
As written in FDA's record.
Approval of PMA 180-day supplement, which requested approval for adding 3T Magnetic Resonance (MR) conditional labeling to the implanted components of the WaveWriter Alpha Spinal Cord Stimulation (SCS) System and WaveWriter Alpha Prime SCS System for head and lower extremities
Source documents
Other decisions for Boston Scientific Corp
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
P130030 · Decided Mar 10, 2026 · 4,453 days after receipt
Device type: STENT, CORONARY (MAF) · Cardiology
7 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.